logo-loader
viewAlphabet Inc

Google parent Alphabet sees first-quarter profit and revenue beat expectations

Alphabet reported a 29% leap in first quarter net income to US$5.43bn, giving earnings per share of US$7.73, well above estimates for US$7.39, as revenue rose to US$24.75bn.

Google on signs
The group saw its advertising revenues rise to US$21.4bn during the quarter, up from just over US$18bn a year ago

Google’s parent Alphabet Inc (NASDAQ:GOOGL) saw its first-quarter profit and revenue beat expectations as its core advertising business continued to grow strongly.

After the New York market close last night, Alphabet reported a 29% leap in first quarter net income to US$5.43bn, giving earnings per share of US$7.73, well above estimates for US$7.39, as revenue rose to US$24.75bn.

For the first quarter of 2016, the internet search giant’s parent had reported net income of US$4.21bn and adjusted earnings per share of US$6.02 on revenue of US$20.26bn.

Advertising and non-advertising revenue jump

The group saw its advertising revenues rise to US$21.4bn during the quarter, up from just over US$18bn a year ago.

Google's non-advertising revenue, which consists mainly of the cloud computing business, the Pixel smartphones and the Play store, also grew dramatically in the quarter, jumping 49.4% to US$3.10bn.

In after-hours trading, Alphabet shares were over 4% higher at US$929.50.

Quick facts: Alphabet Inc

Price: 1345.02 USD

NASDAQ:GOOG
Market: NASDAQ
Market Cap: $927.64 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

33 minutes ago

2 min read